Back to News
Market Impact: 0.35
Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook
Source: marketbeat.com
Healthcare & BiotechCorporate Guidance & OutlookProduct LaunchesCompany Fundamentals
Alnylam Pharmaceuticals highlighted continued momentum for AMVUTTRA in transthyretin-mediated cardiomyopathy and identified upcoming clinical pipeline catalysts. The company also revised its 2026 TTR franchise revenue outlook in response to market changes, creating uncertainty around the longer-term commercial trajectory despite ongoing treatment uptake.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
-0.05
Ticker Sentiment
ALNY0.30
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Asian chip stocks slide as disappointing Qualcomm, Arm earnings weigh
- Snap shares fall over 10% on third-quarter earnings miss
- Leonardo raises 2026 order guidance after strong 9-mth performance
- HelloFresh Q3 core profit tops forecasts as marketing cuts hit orders
- Microsoft declines Nscale Texas expansion ahead of $35 bln IPO - report